Cargando…

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis

Background and Purpose: To quantitatively compare the recurrence patterns of glioblastoma (isocitrate dehydrogenase-wild type) versus grade 4 isocitrate dehydrogenase-mutant astrocytoma (wild type isocitrate dehydrogenase and mutant isocitrate dehydrogenase, respectively) following primary chemoradi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stewart, James, Sahgal, Arjun, Chan, Aimee K M, Soliman, Hany, Tseng, Chia-Lin, Detsky, Jay, Myrehaug, Sten, Atenafu, Eshetu G, Helmi, Ali, Perry, James, Keith, Julia, Jane Lim-Fat, Mary, Munoz, David G, Zadeh, Gelareh, Shultz, David B, Das, Sunit, Coolens, Catherine, Alcaide-Leon, Paula, Maralani, Pejman Jabehdar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247382/ https://www.ncbi.nlm.nih.gov/pubmed/35762826 http://dx.doi.org/10.1177/15330338221109650

Ejemplares similares

Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma
por: Maralani, Pejman Jabehdar, et al.
Publicado: (2021)

ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma
por: Maralani, Pejman Jabehdar, et al.
Publicado: (2021)

30 GY IN 4 STEREOTACTIC BODY RADIOTHERAPY (SBRT) FRACTIONS FOR COMPLEX SPINAL METASTASES: MATURE OUTCOMES SUPPORTING THIS NOVEL REGIMEN
por: Moore-Palhares, Daniel, et al.
Publicado: (2023)

Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events
por: Zeng, K Liang, et al.
Publicado: (2021)

Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events
por: Zeng, K Liang, et al.
Publicado: (2021)

Empirical planning target volume modeling for high precision MRI guided intracranial radiotherapy
por: Stewart, James, et al.
Publicado: (2023)

BIOMARKER STATUS PREDICTS FOR LOCAL CONTROL (LC) FOLLOWING SPINE STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH SPINAL METASTASES
por: Shor, Dana, et al.
Publicado: (2023)

STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR SACRAL METASTASES: DEVIATION FROM RECOMMENDED TARGET VOLUME DELINEATION PREDICTS HIGHER RISK OF LOCAL FAILURE
por: Moore-Palhares, Daniel, et al.
Publicado: (2023)

RE-IRRADIATION FOR RECURRENT HIGH-GRADE GLIOMA: AN ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL AND PREDICTORS OF RADIATION NECROSIS
por: Moore-Palhares, Daniel, et al.
Publicado: (2023)

Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis
por: Karami, Elham, et al.
Publicado: (2019)

A FIRST REPORT ON OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR POSTERIOR ELEMENT ONLY SPINAL METASTASES AND VALIDATION OF RECOMMENDED CLINICAL TARGET VOLUME DELINEATION PRACTICE
por: Burgess, Laura, et al.
Publicado: (2023)

High grade glioma radiation therapy on a high field 1.5 Tesla MR-Linac - workflow and initial experience with daily adapt-to-position (ATP) MR guidance: A first report
por: Tseng, Chia-Lin, et al.
Publicado: (2022)

Comparison of Prospectively Generated Glioma Treatment Plans Clinically Delivered on Magnetic Resonance Imaging (MRI)-Linear Accelerator (MR-Linac) Versus Conventional Linac: Predicted and Measured Skin Dose
por: Wang, Michael H., et al.
Publicado: (2022)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Spine Stereotactic Body Radiotherapy: Indications, Outcomes, and Points of Caution
por: Tseng, Chia-Lin, et al.
Publicado: (2017)

Glioma consensus contouring recommendations from a MR-Linac International Consortium Research Group and evaluation of a CT-MRI and MRI-only workflow
por: Tseng, Chia-Lin, et al.
Publicado: (2020)

Chemical Exchange Saturation Transfer MRI: What Neuro-Oncology Clinicians Need To Know
por: Jabehdar Maralani, Pejman, et al.
Publicado: (2023)

CLINICAL APPLICATION OF SATURATION TRANSFER MRI FOR DIFFERENTIATING TUMOUR PROGRESSION FROM RADIATION NECROSIS IN BRAIN METASTASES
por: Chan, Rachel W, et al.
Publicado: (2023)

Synthesis of diffusion-weighted MRI scalar maps from FLAIR volumes using generative adversarial networks
por: Chan, Karissa, et al.
Publicado: (2023)

Improved dosimetric accuracy with semi‐automatic contour propagation of organs‐at‐risk in glioblastoma patients undergoing chemoradiation
por: Lee, Sangjune, et al.
Publicado: (2019)

PREDICTORS OF TUMOR DYNAMICS DURING A COURSE OF 30-FRACTION RADIOTHERAPY FOR GLIOBLASTOMA
por: Ong, W L, et al.
Publicado: (2023)

Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma
por: Minniti, Giuseppe, et al.
Publicado: (2023)

NGMA-1. Quantification of IDH mutant alleles predicts outcome in diffuse gliomas
por: Voisin, Mathew, et al.
Publicado: (2021)

Role of Angiopoietin-2 in Regulating Growth and Vascularity of Astrocytomas
por: Zadeh, Gelareh, et al.
Publicado: (2010)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

LOCL-16 IMPACT OF MGMT PROMOTER METHYLATION STATUS ON TUMOR DYNAMICS DURING WEEKLY ADAPTIVE RADIOTHERAPY FOR GLIOBLASTOMA
por: Hudson, John M, et al.
Publicado: (2022)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
por: da Silva, Roseli, et al.
Publicado: (2015)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
por: Christians, Arne, et al.
Publicado: (2019)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy
por: Mehrabian, Hatef, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2aovijeibra09emrpab2mek68g